Full-Time

Pharmaceutical Sales

Neuroscience Specialist

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$107.4k - $166.8k/yr

+ Incentive opportunity

Tyler, TX, USA

In Person

Must live within 50 miles of Tyler and travel by car daily throughout the territory.

Bachelor's

Category
Sales & Account Management (1)

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A Bachelor's degree is required.
  • At least one of the following experiences is required: 2 or more years of pharmaceutical or medical device sales experience; 3 or more years of business-to-business or equivalent outside sales experience in regulated, clinical, or customer engagement work; or 2 or more years of clinical healthcare experience, such as Nurse Practitioner, Physician Assistant, Registered Nurse, or similar, with patient-facing, medical education, or therapy-focused responsibilities.
  • The candidate must reside within a commutable distance of 50 miles from Tyler, Texas.
  • The candidate must be able to travel by car daily within the sales territory.
Responsibilities
  • Conduct proactive outreach to healthcare providers on product access, on-label information, and established patient care guidance.
  • Engage customers through virtual or digital tools and direct them to other colleagues as needed.
  • Facilitate speaker programs and organize local provider groups to discuss experiences and outcomes with local or regional leaders.
  • Ensure customer requests are met and solicit feedback on engagement quality.
  • Collaborate compliantly with the ecosystem team to adjust targeting and call point plans.
  • Use insights collected from customer-facing roles to inform local strategy and business goals.
  • Elevate opportunities and feedback to the Area Business Lead, including local market insights.
  • Use competitive data and business reports, including sales data and promotional budgets, to track progress and uncover opportunities.
  • Establish near-term territory priorities based on territory knowledge and business conditions affecting sales results.
  • Respond compliantly to competitive threats and opportunities.
  • Educate office staff on payer guidelines and reimbursement procedures to increase pull-through.
  • Effectively use approved promotional materials.
  • Maintain awareness of internal support-team resources and use them appropriately.
  • Apply market and industry knowledge to overcome objections and influence prescribing habits during office calls.
  • Identify territory professional groups for networking and exposure to potential key opinion leaders.
  • Build relationships with key office and practice personnel, follow through on account needs, and provide accurate information.
  • Deliver balanced office calls and sales presentations using approved marketing materials and technical references, including studies and package inserts, while demonstrating product and competitor knowledge.
Desired Qualifications
  • CNS knowledge is highly valued.
  • Ability to communicate complex clinical information, influence stakeholders, and translate scientific data into clear, practical value propositions.
  • Commitment to ethical business practices and understanding of regulatory standards and company compliance guidance.
  • Ability to assimilate and communicate complex clinical and product information.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.